QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clinical-failure-halts-alectors-dementia-program-company-reduces-workforce

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued...

 td-cowen-downgrades-alector-to-hold

TD Cowen analyst Yaron Werber downgrades Alector (NASDAQ:ALEC) from Buy to Hold.

 cantor-fitzgerald-downgrades-alector-to-neutral

Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector (NASDAQ:ALEC) from Overweight to Neutral.

 hc-wainwright--co-maintains-buy-on-alector-lowers-price-target-to-5

HC Wainwright & Co. analyst Andrew Fein maintains Alector (NASDAQ:ALEC) with a Buy and lowers the price target from $10 ...

 william-blair-downgrades-alector-to-market-perform

William Blair analyst Myles Minter downgrades Alector (NASDAQ:ALEC) from Outperform to Market Perform.

 btig-downgrades-alector-to-neutral

BTIG analyst Thomas Shrader downgrades Alector (NASDAQ:ALEC) from Buy to Neutral.

 alector-says-workforce-reduction-impacts-about-75-employees-restructuring-charges-expected-to-be-about-77m

- SEC Filing

 alector-discontinues-open-label-extension-for-latozinemab-co-to-reduce-workforce-by-about-49

Alector Pipeline OutlookAlector remains focused on advancing a pipeline of programs designed to treat neurodegenerative disease...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION